The AMA has assigned a Category 1 CPT code for Xipere, according to a press release from Bausch + Lomb.
Xipere (triamcinolone acetonide injectable suspension), the first FDA-approved therapy for suprachoroidal use for the treatment of macular edema associated with uveitis, was launched in the U.S. in March 2022.
“The Category 1 code will help facilitate better access and adoption of Xipere and its unique suprachoroidal injection method, which enables targeted delivery of the medication,” Andrew Stewart, president, global pharmaceuticals and international consumer, Bausch + Lomb,